| 1 | 150 mg double-blinded secukinumab | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬
|
| 2 | 150 mg open-label secukinumab | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬
|
| 3 | 300 mg double-blinded secukinumab | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬
|
| 4 | After exclusion of relevant contraindications, participants received subcutaneous ustekinumab/secukinumab therapy. | 2件: Secukinumab Secukinumab (Secukinumab), Ustekinumab | 2件: Ustekinumab
Ustekinumab
,
Secukinumab
(Secukinumab) 💬
| 4件: IL12A IL12A, IL12B, IL17A, IL23A 💬
| 29件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 37 37 💬
|
| 5 | Other: Secukinumab | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 2件: 107 107, 271 💬
|
| 6 | SECUKINUMAB | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 9件: 13 13, 37, 40, 41, 46, 107, 160, 269, 271 💬
|
| 7 | Secukinumab (150 mg) | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬
|
| 8 | Secukinumab (75 mg) | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬
|
| 9 | Secukinumab (AIN457) | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 46 46 💬
|
| 10 | Secukinumab (AIN457) 150 mg s.c. | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬
|
| 11 | Secukinumab 150 mg | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 41 41 💬
|
| 12 | Secukinumab 150 mg (2 injections per dose | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 269 269 💬
|
| 13 | Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection. | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬
|
| 14 | Secukinumab 150 mg/1 mL Solution for injection | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 2件: 37 37, 271 💬
|
| 15 | Secukinumab 150 mg/ml | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬
|
| 16 | Secukinumab 150 milligram [Cosentyx] | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬
|
| 17 | Secukinumab 150mg | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 37 37 💬
|
| 18 | Secukinumab 150mg s.c. | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬
|
| 19 | Secukinumab 300 mg | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 41 41 💬
|
| 20 | Secukinumab 300 mg, s.c. | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 41 41 💬
|
| 21 | Secukinumab 300mg | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 37 37 💬
|
| 22 | Secukinumab 300mg s.c. | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬
|
| 23 | Secukinumab 75 mg/0.5 ml Solution for injection | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬
|
| 24 | Secukinumab Injection | 1件: Secukinumab Secukinumab (Secukinumab) | 1件: Secukinumab
Secukinumab
(Secukinumab) 💬
| 1件: IL17A IL17A 💬
| 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 160 160 💬
|
| 25 | Secukinumab was administered in a weight-adapted dosing regimen ? Dupilumab was administered at a dose dependent on the patient's weight and age | 2件: Dupilumab Dupilumab, Secukinumab (Secukinumab) | 2件: Secukinumab
Secukinumab
(Secukinumab),
Dupilumab
💬
| 2件: IL17A IL17A, IL4R 💬
| 11件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 1件: 160 160 💬
|